Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adenocarcinoma × Atu027 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Pancreatic Ductal 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Gemcitabine 22 Fluorouracil 12 Cisplatin 11 Carboplatin 11 Capecitabine 11 pembrolizumab 10 Pemetrexed 10 Paclitaxel 10 Oxaliplatin 10 130-nm albumin-bound paclitaxel 8 zolbetuximab 7 Leucovorin 7 trastuzumab deruxtecan 6 Ramucirumab 6 Albumin-Bound Paclitaxel 6 Nivolumab 4 Drug Therapy 4 Docetaxel 4 Bevacizumab 4 vandetanib 3 cemiplimab 3 Everolimus 3 EC145 3 tislelizumab 2 technetium 99m etarfolatide 2 spartalizumab 2 pralsetinib 2 osimertinib 2 nimotuzumab 2 napabucasin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡